A Phase 1, Randomized, Double Blind (Sponsor-Open), Placebo Controlled, Dose Escalation, Multiple Dose Study To Investigate Safety, Tolerability, And Pharmacokinetics Of PF-00868554 In Japanese Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 20 Jan 2010
At a glance
- Drugs Filibuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Pfizer
- 20 Jan 2010 Planned initiation date changed to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 20 Jan 2010 Planned end date changed from 1 Apr 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
- 23 Oct 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.